Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the
ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs …

Introduction: The mortality of coronavirus disease 2019 (COVID-19) is frequently driven by
an injurious immune response characterized by the development of acute respiratory …

As of mid-April, 2020, severe acute respiratory syn drome coronavirus 2 (SARS-CoV-2), the
coronavirus respon sible for COVID-19, has infected more than 4· 4 million people …

With the emergence of COVID-19 extensive research began to identify medications,
candidate compounds and other therapeutic approaches. The complex virology of COVID …

Humans have witnessed three deadly pandemics so far in the twenty-first century which are
associated with novel coronaviruses: SARS, Middle East respiratory syndrome (MERS), and …

Many viral respiratory infections can cause severe acute respiratory symptoms leading to
mortality and morbidity. In the spring of 2003, the severe acute respiratory syndrome (SARS) …

Coronavirus disease (COVID‐19) is now dominating the lives of everyone, and its history is
constantly being rewritten. This article gives a brief account of the story so far: where SARS …

The 2019 novel coronavirus disease (COVID‐19) now is considered a global public health
emergency. One of the unprecedented challenges is defining the optimal therapy for those …

The outbreak of the novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)
responsible for coronavirus disease 2019 (COVID-19) has developed into an …

Summary Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019,
and has since become a pandemic. Groups from China identified and sequenced the virus …